Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 197

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 197
---
157,206 |   |
| Share-based payment to Chairman                               |     |                    |   101,458 |     |   |           |   |
| All directors and officers as a group                         |     | $                  | 1,226,506 |     | $ | 1,147,696 |   |

119 For so long as we qualify as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic companies regarding disclosure of the compensation of certain executive officers on an individual basis. Pursuant to applicable Canadian Securities Laws, we are required to disclose the annual compensation of each of the following:

| a. | the Company’s Chief Executive Officer (“CEO”); |

| b. | the Company’s Chief Financial Officer (“CFO”); |

| c. | the Company’s three most highly compensated executive officers, other than the CEO and CFO, who were serving as executive officers 
 as at the applicable year end, and whose total compensation was more than $150,000 for the financial year ended; and               |

| d. | each individual who would be a named executive officer under paragraph (c) but for the fact that the individual was neither an executive 
 officer of the Company, of which there are none.                                                                                         |

This disclosure will not be as extensive as that required of a U.S. domestic issuer. As of October 31, 2025, options to purchase 5,521 Common Shares were granted to our directors and executive officers under our Omnibus Equity Incentive Plan, or the Omnibus Plan. The options have at a weighted average exercise price of $429.24 per share. The following table sets forth information regarding options granted to our executive officers and directors as of the date hereof that are outstanding as of the date of this filing:

| Name             |     | Grant Date       |     | Stock   
 Options |       |     | Weighted Average 
 Options          
 Exercise Price   
 (USD)            |        |     | Expiration Date  |
|:-----------------|:----|:-----------------|:----|:--------|------:|:----|:-----------------|-------:|:----|:-----------------|
| Adi Zuloff Shani |     | May - July 2021  |     |         | 1,334 |     | $                | 481.52 |     | May - July 2026  |
|                  |     | February 1,